Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: April 21, 2026
Context: The filing incorporates a press release regarding the Company's participation in the Society of Breast Imaging Symposium 2026 and highlights revenue performance for the first quarter of 2026.
Key Financial Metrics
- Revenue Growth: U.S. ProSense® revenue increased by more than 30% in the first quarter of 2026 compared to the first quarter of 2025.
- Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide clear values for net income, operating cash flow, profit margins, total debt, or liquidity positions.
Material Changes
The primary material change reported is the significant year-over-year growth in U.S. ProSense® revenue for the first quarter of 2026, exceeding a 30% increase compared to the same period in 2025.
Guidance, Outlook, and Risks
Management Commentary: The Company highlighted its participation in the Society of Breast Imaging Symposium 2026 alongside the revenue milestone.
Guidance and Risks: The filing text does not provide specific forward-looking guidance, updated risk factors, or details on contingencies beyond the press release title.
Investor Verification Checklist
- Verify the absolute dollar value of the U.S. ProSense® revenue for Q1 2026 and Q1 2025 to assess the scale of the 30%+ increase.
- Review the full text of the press release (Exhibit 99.1) for details on the Society of Breast Imaging Symposium outcomes.
- Check subsequent filings for comprehensive Q1 2026 financial statements, as this 6-K only summarizes specific revenue highlights.